ROBERT S. RADIE - Corporate Board Profile

ROCKWELL MEDICAL, INC.

Filing Date	Source Excerpt
2020-04-20	Robert S. Radie has been a director since March 2020. ... We believe that Mr. Radie’s prior executive management, finance, commercialization, capital raising, investor relations and public company experience in the life sciences industry qualifies him for service as a director of our Company. ... Directors who are employed by the Company do not receive separate compensation for their service as a director.
2021-04-30	Robert S. Radie has been a director since March 2020. ... Mr. Radie has served as Chief Executive Officer and Chairman of the board of directors of Neuraptive Therapeutics, Inc. ... We believe that Mr. Radie’s prior executive management, finance, commercialization, capital raising, investor relations and public company experience in the life sciences industry qualifies him for service as a director of our Company.
2022-04-08	Robert S. Radie(1)(3) 58 Director (3) Member of the Governance and Nominating Committee. (1) Member of the Compensation Committee. Chairman of the Board. 2021 Director Compensation: Fees Earned or Paid in cash ($) 62,678, Restricted Stock Unit Awards ($) 44,915, Option Awards ($) 42,319, Total ($) 149,912.
2023-04-17	Robert S. Radie has been a director since March 2020 and Chairman of the Board since April 2022. Mr. Radie has served as Chief Executive Officer and Chairman of the board of directors of Neuraptive Therapeutics, Inc., a private, clinical stage company focused on improving outcomes in traumatic peripheral nerve injury, since June 2020. He previously served as President and Chief Executive Officer and a member of the board of directors of Zyla Life Sciences, a life sciences company, from March 2012 to October 2019. From November 2010 to October 2011, Mr. Radie served as President and Chief Executive Officer of Topaz Pharmaceuticals Inc., a specialty pharmaceutical company. From March 2009 to November 2010, Mr. Radie served as President and Chief Executive Officer of Transmolecular, Inc., a biotechnology company, after serving as a consultant to Transmolecular from December 2008 through March 2009. From September 2007 to September 2008, Mr. Radie served as the Chief Business Officer of Prestwick Pharmaceuticals, Inc., a specialty pharmaceutical company. Before joining Prestwick, Mr. Radie served in senior management positions with a number of pharmaceutical and biotechnology companies, including Morphotek, Inc., Vicuron Pharmaceuticals, Inc. and Eli Lilly and Company. Mr. Radie has been a member of the board of directors of Paratek Pharmaceuticals since November 2014, ValSource Inc. since October 2020 and has also served as a director of Horse Power for Life, a nonprofit organization dedicated to improving the quality of life for individuals diagnosed with cancer, since 2006. He previously served as a member of the board of directors of Veloxis Pharmaceuticals A/S from June 2016 to February 2020 and Affinium Pharmaceuticals, Ltd. from July 2012 to March 2014. He also served as a Director for Life Science PA, an industry advocacy group in Pennsylvania. Mr. Radie received his B.S. in Chemistry from Boston College. We believe that Mr. Radie’s prior executive management, finance, commercialization, capital raising, investor relations and public company experience in the life sciences industry qualifies him for service as a director of our Company.
2024-04-15	Robert S. Radie has been a director since March 2020 and Chairman of the Board since April 2022. Mr. Radie serves as Chairman of the Board. He served on the Nominating and Governance Committee and Compensation Committee during 2023. 2023 Director Compensation shows $105,000 fees earned or paid in cash and $65,000 restricted stock unit awards, totaling $170,000.